

How Much Data Do We Need, and Where Do We Get It?

Joe Deasy, PhD

Department of Medical Physics



Memorial Sloan Kettering
Cancer Center

Thanks to


- Harini Veeraraghavan, PhD
- Jung Hun Oh, PhD
- Aditya Apte, PhD
- Maria Thor, PhD
- Mireia Crispin-Ortuzar, PhD
- Andreas Rimner, MD
- Matthew Hellman, MD
- Charles Rudin, MD
- John Humm, PhD
- Margie Hunt, MS
- Amita Dave, PhD
- Neelam Tyagi, PhD
- Nancy Lee, MD
- Heiko Shoeder, MD
- Sang Ho Lee, PhD
- Milan Grkovski, PhD
- And many more...!

Disclosure:

Co-founder of PAIGE.AI, a computational pathology company.

Funding support is gratefully acknowledged:
NIH (R01 and Cancer Center P30 Core Grant),
The Breast Cancer Research Foundation,
Philips, Corp.
Varian Oncology.

Predictive modeling: inputs



Predictive modeling sources and outputs

Sources

- Planning dose-volume histograms
- Dose-mapping to identify sensitive regions
- Other planning data: e.g., segmented structures
- Clinical variables
- Radiomics from
 - Diagnostic imaging workup
 - Planning/simulation scan
 - Daily setup images
- Genomic data
 - Tumor actionable mutations
 - RNA, copy number variations
 - Key Germline mutations (BRCA1, BRCA2)
 - Germline genome wide association studies
- Pathology: pathomics

Prediction outputs

- Overall survival
- Local control at a give time point
- Risk of complication (NTCP)
- Likelihood of local control (TCP)
- Genetically stratified risk of complications
- Image segmentation
- Cancer subtype
- Likelihood of response to a given cancer drug
- Likelihood of response to immune therapy
- Risk of developing cancer
-

The prediction modeling pipeline



Must be comparable!

*How do you keep from fine tuning the model **too much** in attempting to agree with the input data?*

Cross-validation!



7

Set-aside cross-validation costs data that could be used for fitting: so why do it?

Rigor: to convince other people (and yourself) that there has been no cheating ('information leakage') that informed the 'hyper parameter' choices.

For small-ish datasets you can use leave-one-out cross validation as the only validation method.

Warning: The entire **supervised** component of the modeling process must be contained within the LOOCV loop, with no prior 'fiddling' with the method. Filing a statistical plan works here as well.

Another way to increase rigor: pre-file your statistical analysis plans (Dekker)



Validation is a higher level of the scientific process than discovery...and it is easier!

- Better
↓
1. Internal: good cross validation, **including feature selection**
 2. Internal set-aside validation
 3. External: same publication
 4. External: separate publication/group

Traditional statistical rule of thumb:
10 observations per predictor variable.

Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. *Journal of clinical epidemiology*. 1996 Dec 1;49(12):1373-9.

So for a modest-sized model (~5 or fewer variables), 50 'events' is probably adequate.

Theoretically: if the model/hypothesis is not known,
the bound on the error is not simple:

$$R(h) \leq R_{\text{emp}}(h) + C(|\mathcal{H}|, N, \delta)$$

$$R(h) \leq R_{\text{emp}}(h) + \sqrt{\frac{8d_{VC}(\ln \frac{2m}{d_{VC}} + 1) + 8 \ln \frac{4}{\delta}}{m}}$$


<https://mostafa-samir.github.io/ml-theory-pt2/>


If the model to be tested is known
(Hoeffding's inequality):

This is why validation with a
fixed hypothesis is so much
easier!

Epsilon is a given bound on the error
m is the size of the dataset
h is a given model/hypothesis

<https://mostafa-samir.github.io/ml-theory-pt2/>





Radiomics: "Immunotherapy benefit for lung cancer patients is associated with tumor heterogeneity determined from computed tomography radiomic entropy feature"


Approach:

- measures of heterogeneity predict late (> 1 yr.) immunotherapy response.
- 62 NSCLC patients treated with pembrolizumab.
- Four radiomic measures of heterogeneity were extracted from longitudinal CT scans, including entropy of values over small patches.
- High entropy implies neighboring voxels are relatively dissimilar in intensity.

Key result:

- High entropy at first treatment scan predicts durable response.
- The change in entropy from baseline is more important than baseline entropy.


H. Veeraraghavan¹, M. Hellmann², H. Rizvi², J. Jiang¹, D. Halpenny³, A. Snyder², ..., J. Deasy¹, MSKCC Depts. of ¹ Medical Physics, ² Medicine, and ³ Radiology (in review)




J. Clin. Radiol. Oncol. 2016 Apr 7; doi:10.1002/jco.24890 (first viewed at jco)

Breast cancer subtype intertumor heterogeneity: MRI-based features predict results of a genomic assay.

Subramanian T, Di JH, Giatromanolaki SC, Vemireddyvenkatachalam A, Acharya A, Chakrabarti SK, Datta JC, Nanda EA.



N=95



$$Y \text{ (ODxBS)} = -5.95 \times \text{histonol}[\text{Percentcent 1}] + 6.29 \times \text{histonol}[\text{Percentcent 3}] + 3.90 \times \text{nuclear grade} + 4.12$$


R²=0.23

Do we know the best machine learning tools for radiomics

- “No,” but this is probably less of an effect compared to
 - variability between imaging systems/calibration practices/protocols
 - Data starvation
- Low dimensional modeling should always be tried
- If dataset is particularly rich, higher dimensional data analysis may be justified, with careful control of the risk of overfitting

Combined PET and CT radiomics features predict maximum FMISO uptake in head and neck cancer (Crispin-Ortuzar et al., Radiother. Oncol., 2018)

- FDG PET + contrast-enhanced CT to predict maximum FMISO TBR
- 79 training, 42 hold-out validation
- LASSO + 10x10-fold CV
- Selected predictors:
 - P90 FDG SUV
 - Long run high grey level emphasis in low-FDG subregion
- Validation AUC = 0.83



Radiomics analysis of pulmonary nodules in low-dose CT for early detection of lung cancer

Wenqin Chen, Jiong Huan Qiu, and Baohong Hu
Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY 10025, USA

Chen Du Liu
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10025, USA

Feng Jiang
Department of Pathology, University of Wisconsin School of Medicine, Wisconsin, WI 53706, USA

Wenqin Chen and Charles W. Fite
Department of Diagnostic Radiology and Nuclear Medicine, University of Wisconsin School of Medicine, Wisconsin, WI 53706, USA


Archieva Hricak
Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10025, USA


James G. Hirschman, Joseph C. Deasy, and Wei Lu*
Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY 10025, USA

(Received 14 September 2017; revised 5 February 2018; accepted for publication 7 February 2018; published 17 March 2018)

(Medical Physics, 2018)

N=72






Breast Cancer Molecular Subtype Classifier That Incorporates MRI Features

J. MAGN. RESON. IMAGING 2016;44:122-129.

Elizabeth J. Sutton, MD,^{1*} Rikway J. Lindenberg, MD, PhD,^{1,2} Jung-Han Oh, PhD,³ Hyeon Jeon, PhD,^{1,2} Donghyun P. Jeon, PhD,^{1,2} Yoonhee S. Yoon, PhD,^{1,2} Elizabeth A. Morris, MD,¹ and Joseph D. Deary, PhD,^{1,2}




N=178
LOOCV

Prediction accuracy for IDC subtype was 81.4%


Automatic classification of prostate cancer Gleason scores from multiparametric magnetic resonance images

Yan Yan,^{1*} Jiefei Yang,^{1,2,3,4} Andrew Wilson,¹ Tamas Csontos,¹ Karolina Marumet,¹ Robert M. Varga,¹ Yixi Zou,¹ Feihong Zhou,¹ and Joseph D. Deary,^{1,2}

¹Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY; ²Department of Biophysics, Memorial Sloan-Kettering Cancer Center, New York, NY; ³Department of Biomedical Engineering, Memorial Sloan-Kettering Cancer Center, New York, NY; ⁴Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY



N=217



A key was augmenting the learning dataset with simulated data.




ARTICLE

Received 25 Nov 2015 | Accepted 20 Apr 2016 | Published 7 Jun 2016 | Updated 7 Aug 2016


Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach

Hugo J.M.L. Kantz^{1,2,3,4*}, Simonne Koo Walsap^{1,2,3}, Robin Y.H. Leung¹, Clorinda Perna^{1,2}, Patrick Croppmann², Sara Carvello¹, Johan Buisson², René Albrecht^{2,3}, Benjamin Hübner-Kahle², Derek Korycki², Travis Huxton¹, Marjolijn M. Kooijman², C. René Leemans², André Dekker¹, Joke Quackenbush⁴, Robert J. Gillies⁴ & Polina Lantini¹

N=474, training
324, testing (NSCLC)
231, testing (H&N)
7 cohorts



Note the emphasis on reproducible features and dimensional reduction!




Pooled cohort analysis demonstrates the importance of rectal sparing in preventing late rectal bleeding

M Trier¹, A Jorjane², M J Zolty³, G Krieger⁴, A Karabak⁵, M Beyer⁶, M Liu⁷, N J Nasser⁸, S R Petroni⁹, V Minicucci¹⁰ and J O Hong¹

¹Dept of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, USA
²Dept of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, USA
³Division of Clinical Cancer Epidemiology, Dept. of Oncology, Institute of Clinical Sciences, St. Helier, Jersey, University of the University of Southampton, Southampton, UK
⁴Dept of Oncology, Radcliffe University Hospital, Oxford, UK
⁵Dept of Oncology, Radcliffe University Hospital, Oxford, UK
⁶St. Jude Children's Cancer Agency, Vincent Cancer Center, Vancouver, USA
⁷Dept of Radiation, Medicine and applied sciences, University of California San Diego, La Jolla, USA

- 989 patients, 5 institutions
- treated with 3DCRT or IMRT to
- 70-86.4Gy@1.8-2.0Gy/fraction



SCIENTIFIC REPORTS

OPEN Computational methods using genome-wide association studies to predict radiotherapy complications and to identify correlative molecular processes

Received: 14 October 2016
Accepted: 12 January 2017
Published: 12 January 2017

Yang Yang¹, Liang Zhang¹, Jian Chen¹, Shuang Li¹, Shaojun Zhang¹, Jie Zhang¹, Shuang Li¹


Training dataset

- 243 samples
- 49 events
- 749 SNPs ($p < 0.001$; Chi-square test)

- Validation dataset

- 122 samples
- 25 events


Random Forest



Dataset for RB

- Outcome: rectal bleeding
 - RTOG ≤ 1 (coded 0) vs RTOG ≥ 2 (coded 1)
- Data split: rectal bleeding
 - Training dataset
 - 243 samples
 - 49 events
 - 749 SNPs ($p < 0.001$; Chi-square test)
 - Validation dataset
 - 122 samples
 - 25 events
- 5-fold CV or bootstrapping with 100 iterations
- Additive model
 - Coded as the number of rare alleles

Results for RB using validation data




"Deep learning enables fully automatic tumor segmentation and synthesis of MRI from CT images"

Successfully segmented 1300 NSCLC tumors from three datasets irrespective of tumor size, location, and malignancy.

Our method learns to synthesize MRI from CT images by training with highly limited number of MRI (n=9) with unrelated CT scans (n=300)

Our method has auto-segmented largest number of lung tumors published



Red - Expert, Blue - Algorithm

Awarded Best in Physics, AAPM 2018



CT image

State-of-art

Cycle-GAN

removes

tumor on

synthesis


Our method

preserves


tumor

Slide courtesy: Harini Veeraghavan, Jue Jiang

Towards personalized dose-escalation in non-small cell lung cancer: Validation of published models





The Computational Environment for Radiotherapy Research (CERR)




Radiomics Image Quantifier (RIQ) Toolbox in CERR, Aditya Apte et al.

www.github.com/cerr/CERR



Different ways to compute Haralick entropy lead to different feature maps

...it depends on the predictive modeling activity



Source: PERSONAL OPINION BASED ON 15 yrs. MODELING EXPERIENCE
(obviously a needed area of research!)
